Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease is a research paper published in Annals of Neurology (2020). On theSindex it has a DataRank of 0. It has been cited 124 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCRR NIH HHS
Grant: UL1 RR031975
NCATS NIH HHS
Grant: UL1 TR000101
National Institutes of Health
Grant: 1UL1RR031975-01
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
National Institutes of Health
Grant: 3UL1TR000101-05S2
Georgetown-Howard Universities Center for Clinical and Translational Science (GHU
Alzheimer's Drug Discovery Foundation
National Institutes of Health
National Center for Advancing Translational Sciences
FWCI
8.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
Additional file 1 of Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
Additional file 1 of Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling
Additional file 1 of Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling